Shares of Solventum Co. (NYSE:SOLV – Get Free Report) have been assigned an average recommendation of “Hold” from the eleven brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $74.71.
SOLV has been the subject of several research reports. Wells Fargo & Company raised their price target on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday. Bank of America lifted their target price on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday. Morgan Stanley lifted their target price on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Piper Sandler lifted their target price on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a report on Friday. Finally, Mizuho started coverage on Solventum in a report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 target price for the company.
Get Our Latest Research Report on Solventum
Institutional Inflows and Outflows
Solventum Trading Down 4.7 %
Shares of Solventum stock opened at $79.56 on Friday. The business has a fifty day simple moving average of $72.51 and a two-hundred day simple moving average of $69.88. Solventum has a 1 year low of $47.16 and a 1 year high of $96.05. The company has a market capitalization of $13.74 billion and a price-to-earnings ratio of 28.93. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.
Solventum Company Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Recommended Stories
- Five stocks we like better than Solventum
- The Risks of Owning Bonds
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 5 Best Gold ETFs for March to Curb Recession Fears
- NYSE Stocks Give Investors a Variety of Quality Options
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.